PubRank

A M Storniolo

Author PubWeight™ 51.78‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997 29.02
2 A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 1996 4.07
3 A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 2008 1.66
4 Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 1997 1.56
5 Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 2009 1.43
6 Recombinant human erythropoietin therapy for anemic cancer patients receiving cisplatin chemotherapy. Cancer J Sci Am 2006 1.27
7 A review of hemolytic uremic syndrome in patients treated with gemcitabine therapy. Cancer 1999 1.23
8 Rapid superselective high-dose cisplatin infusion for advanced head and neck malignancies. Head Neck 1992 1.22
9 Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 1994 1.11
10 Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther 2011 1.00
11 Modeling hot flushes and quality of life in breast cancer survivors. Climacteric 2010 1.00
12 Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer 2010 0.99
13 A pilot clinical/pharmacological study of the protein kinase C-specific inhibitor safingol alone and in combination with doxorubicin. Clin Cancer Res 1997 0.98
14 Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol 1992 0.90
15 Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer 2009 0.88
16 Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. Br J Cancer 2013 0.87
17 Sponge-gel-supported histoculture drug-response assay for head and neck cancer. Correlations with clinical response to cisplatin. Arch Otolaryngol Head Neck Surg 1994 0.84
18 "Decadose" effects of cisplatin on squamous cell carcinoma of the upper aerodigestive tract. II. Clinical studies. Laryngoscope 1996 0.80
19 High-dose carboplatin chemotherapy with GM-CSF and peripheral blood progenitor cell support: a model for delivering repeated cycles of dose-intensive therapy. Cancer Treat Rev 1993 0.78
20 A dose-escalation study of carboplatin/cyclophosphamide/etoposide along with autologous bone marrow or peripheral blood stem cell rescue. Semin Oncol 1992 0.78
21 Drug response of head and neck tumors in native-state histoculture. Arch Otolaryngol Head Neck Surg 1991 0.76
22 Surgery vs chemotherapy. Arch Otolaryngol Head Neck Surg 1992 0.75
23 Spontaneous hemoperitoneum in two patients with myeloproliferative disorders. Am J Hematol 1987 0.75